Drugs / QIV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05596734 Background | Oct 2022 → Dec 2023 | COVID-19, influenza | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05596734 ↗ |
| Modality | Vaccine | “commercially licensed quadrivalent influenza vaccine (QIV)” NCT05596734 ↗ |